Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2][3]. - The company is a leading domestic manufacturer of non-invasive ventilators and masks, being the first domestic company to receive FDA certification for non-invasive ventilators, with products sold in over 100 countries [2][3]. R&D and Patents - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents, 404 utility model patents, and 146 design patents. It also has 266 overseas patents, including 45 in the U.S. and 38 in Europe [3]. Financial Performance Revenue - For the first three quarters of 2025, the company reported a revenue of 808 million CNY, a year-on-year increase of 34.24%. The revenue for Q3 alone was 264 million CNY, up 20.22% year-on-year [4]. - Domestic revenue for the first three quarters was 251 million CNY, a growth of 5.51%, while overseas revenue reached 558 million CNY, marking a significant increase of 52.96% [5]. Product Segmentation - Revenue from home ventilators accounted for 521 million CNY (64.51% of total revenue), with a year-on-year growth of 39.07%. Consumables generated 262 million CNY (32.38% of total revenue), growing by 27.26% [6]. Gross Margin - The gross margin for the first three quarters of 2025 was 52.37%, an increase of 1.17% compared to the previous year. The gross margin for Q3 was 52.79%, up 2.47% year-on-year [9]. Market Insights - In Q3, overseas revenue was 205 million CNY, with a year-on-year growth of 40.41% and a quarter-on-quarter growth of 11.92%. The U.S. market contributed significantly, with a year-on-year increase of 63.46% [7]. - The company holds a 8.9% market share in Europe, ranking third, with plans to expand its cloud platform through the integration of over a thousand distributors [9]. Future Outlook - The company is transitioning from an online distribution model to a direct sales model, expecting to see performance improvements starting in Q4 2025. New product registrations, including portable oxygen machines, are anticipated to contribute to domestic revenue growth [10]. - The company has received product registration in Canada, with an estimated annual market potential of 150,000 units [10]. Strategic Initiatives - The company is actively pursuing mergers and acquisitions, focusing on high-potential companies in precision motor and medical technology sectors to enhance its core competitiveness [10]. - It has achieved significant localization in its supply chain, ensuring domestic production of core components, which enhances cost efficiency and technical independence [10].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [15]. Core Insights - The company is expected to experience a rapid growth phase from 2025 to 2027, driven by the end of inventory cycles in overseas markets and the introduction of new products, including a noiseless cotton breathing machine [4][13]. - The domestic market is anticipated to benefit from a 30% national subsidy for home respiratory devices starting in 2025, which will enhance market penetration [4][13]. - The company's shift from a distribution model to direct sales is expected to improve factory prices and gross margins, further accelerating domestic growth [4][13]. Summary by Sections Company Overview - The company is a leading player in the home respiratory device market, with a comprehensive product line that includes single-level and dual-level breathing machines, medical breathing machines, sleep monitors, and high-flow humidified oxygen therapy devices [11][70]. Market Dynamics - The global home respiratory machine market reached approximately $2.71 billion in 2020, with the Chinese market size at about 1.23 billion yuan [9][60]. - The market for ventilatory masks was valued at $1.62 billion globally in 2020, with a compound annual growth rate (CAGR) of 9.7% from 2016 to 2020 [9][65]. Competitive Landscape - The global market for home non-invasive breathing machines is concentrated, with major players including ResMed, Philips, and the company itself, which holds the second-largest market share globally [10][69]. - In the breathing machine market, ResMed accounted for 40.3% of the global market share in 2020, while the company held a 26.6% share in China [10][69]. Product Performance - The company's new noiseless cotton breathing machine is expected to enhance its market share in overseas markets due to its effective noise reduction capabilities [12][76]. - The company has a strong focus on research and development, holding 633 domestic patents and 202 international patents, including 39 in the United States and 30 in Europe [76]. Financial Projections - The company is projected to achieve net profits of 255 million yuan, 332 million yuan, and 433 million yuan for the years 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (PE) ratios of 31.30, 23.99, and 18.40 [13].